GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Current Accrued Expense

PHVS (Pharvaris NV) Current Accrued Expense : $13.45 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Current Accrued Expense?

Pharvaris NV's Current Accrued Expense for the quarter that ended in Mar. 2025 was $13.45 Mil.

Pharvaris NV's quarterly Current Accrued Expense increased from Sep. 2024 ($8.28 Mil) to Dec. 2024 ($10.22 Mil) and increased from Dec. 2024 ($10.22 Mil) to Mar. 2025 ($13.45 Mil).

Pharvaris NV's annual Current Accrued Expense declined from Dec. 2022 ($8.39 Mil) to Dec. 2023 ($5.64 Mil) but then increased from Dec. 2023 ($5.64 Mil) to Dec. 2024 ($10.22 Mil).

Pharvaris NV Current Accrued Expense Historical Data

The historical data trend for Pharvaris NV's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Current Accrued Expense Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial 4.37 3.18 8.39 5.64 10.22

Pharvaris NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.64 13.20 8.28 10.22 13.45

Pharvaris NV Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Pharvaris NV Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharvaris NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Current Accrued Expense
Comparable Companies
GERN ELVN NRIX RCUS ZYME MLYS NTLA SYRE GYRE XFOR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
9EN:Germany
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Website
https://www.pharvaris.com
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.